Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease

by @JTC_PALIdev | Sep 6, 2023 | Press Releases

– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024 – Inflammatory bowel disease (IBD) represents a multi-billion dollar market...

Palisade Bio Reports Second Quarter 2023 Financial Results

by @JTC_PALIdev | Aug 11, 2023 | Press Releases

– Company accelerating late-stage corporate development activities to in-license/acquire synergistic assets to build GI-focused pipeline – Strong financial position with cash to fund operations through 2024 Carlsbad, CA, Aug. 11, 2023 — Palisade Bio,...

Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

by @JTC_PALIdev | Aug 9, 2023 | Press Releases

– Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery Carlsbad, CA, Aug. 09, 2023 — Palisade Bio (Nasdaq: PALI), a biopharmaceutical company...

Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

by @JTC_PALIdev | Jul 5, 2023 | Press Releases

Topline data expected in Q3 2023 Carlsbad, CA, July 05, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the...

Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

by @JTC_PALIdev | Jun 14, 2023 | Press Releases

Live webcast fireside chat on Thursday, June 22nd at 11:30 AM ET Carlsbad, CA, June 14, 2023 — Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D....

Palisade Bio Promotes J.D. Finley to Chief Executive Officer

by @JTC_PALIdev | Jun 1, 2023 | Press Releases

Carlsbad, CA, June 01, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley has...